Ideaya Biosciences

Ideaya Biosciences company information, Employees & Contact Information

IDEAYA is an oncology-focused precision medicine company. Our teams are committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. We are advancing therapeutics that have the potential to be first-in-class and/or best-in-class, with a primary focus in synthetic lethality – an emerging class of precision medicine targets. IDEAYA is headquartered in South San Francisco, California.

Company Details

Employees
203
Founded
-
Address
7000 Shoreline Court,
Phone
(650)491-9600
Email
in****@****bio.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
South San Francisco, California
Looking for a particular Ideaya Biosciences employee's phone or email?

Ideaya Biosciences Questions

News

IDEAYA Biosciences to Participate in Upcoming November 2025 Investor Relations Events - Morningstar

IDEAYA Biosciences to Participate in Upcoming November 2025 Investor Relations Events Morningstar

IDEAYA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update - PR Newswire

IDEAYA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update PR Newswire

IDEAYA Biosciences CEO Fireside Chat: Precision Medicine Updates at BTIG Conference - Stock Titan

IDEAYA Biosciences CEO Fireside Chat: Precision Medicine Updates at BTIG Conference Stock Titan

IDEAYA Biosciences Appoints Douglas B. Snyder as Senior Vice President, General Counsel - PR Newswire

IDEAYA Biosciences Appoints Douglas B. Snyder as Senior Vice President, General Counsel PR Newswire

IDEAYA Biosciences Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid Tumors - PR Newswire

IDEAYA Biosciences Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid Tumors PR Newswire

IDEAYA Biosciences Receives Fast Track Designation for Darovasertib Combination Therapy with Crizotinib for the Treatment of Metastatic Uveal Melanoma - PR Newswire

IDEAYA Biosciences Receives Fast Track Designation for Darovasertib Combination Therapy with Crizotinib for the Treatment of Metastatic Uveal Melanoma PR Newswire

IDEAYA Biosciences Raises $94 Million Crossover Series B Financing - PR Newswire

IDEAYA Biosciences Raises $94 Million Crossover Series B Financing PR Newswire

Top Ideaya Biosciences Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant